RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep demonstrates 69% ORR in pancreatic cancerShould read : TCRs typically recognise antigen within the context of an MHC molecule and the expansion of cytotoxic CD8+ immune effector T cells. which serves both as an adhesion molecule for class I MHC molecules and as a coreceptor with the TCR for T cell activation.
ONCY Aware-1 and Bracelet-1 breast cancer clinical studies showed that treatment with pelareorep resulted in the expansion of cytotoxic CD8+ immune effector T cells which then causes an out-numbering of immunosuppressive Treg cells.
In so doing, ONCY showed how pelareorep is able to remodel the tumor microenvironment (TME) and turn cold tumors, like pancreatic cancer, into ‘hot’ inflamed tumors that demonstrate high responses to immune checkpoint inhibitors (CPIs).